Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary chondrocytes and mediated by TAK1 kinase activity.

van Caam A, Madej W, Garcia de Vinuesa A, Goumans MJ, Ten Dijke P, Blaney Davidson E, van der Kraan P.

Arthritis Res Ther. 2017 May 31;19(1):112. doi: 10.1186/s13075-017-1302-4.

2.

Signaling by TGF-betas in tubule cultures of adult rat testis.

Chan KH, Galuska SP, Kudipudi PK, Riaz MA, Loveland KL, Konrad L.

Am J Transl Res. 2017 Mar 15;9(3):1173-1182. eCollection 2017.

3.

Regulation of hepcidin expression by inflammation-induced activin B.

Kanamori Y, Sugiyama M, Hashimoto O, Murakami M, Matsui T, Funaba M.

Sci Rep. 2016 Dec 6;6:38702. doi: 10.1038/srep38702.

4.

Examining Crosstalk among Transforming Growth Factor β, Bone Morphogenetic Protein, and Wnt Pathways.

Coster AD, Thorne CA, Wu LF, Altschuler SJ.

J Biol Chem. 2017 Jan 6;292(1):244-250. doi: 10.1074/jbc.M116.759654. Epub 2016 Nov 28.

5.

c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.

Morrison CD, Allington TM, Thompson CL, Gilmore HL, Chang JC, Keri RA, Schiemann WP.

Oncotarget. 2016 Nov 8;7(45):72777-72794. doi: 10.18632/oncotarget.11909.

6.

MicroRNA-93-5p may participate in the formation of morphine tolerance in bone cancer pain mouse model by targeting Smad5.

Xiao WF, Li YS, Lou W, Cai T, Zhang S, Hu XY, Zhang XW, Luo W.

Oncotarget. 2016 Aug 9;7(32):52104-52114. doi: 10.18632/oncotarget.10524.

7.

Transforming Growth Factor β1 (TGF-β1) Activates Hepcidin mRNA Expression in Hepatocytes.

Chen S, Feng T, Vujić Spasić M, Altamura S, Breitkopf-Heinlein K, Altenöder J, Weiss TS, Dooley S, Muckenthaler MU.

J Biol Chem. 2016 Jun 17;291(25):13160-74. doi: 10.1074/jbc.M115.691543. Epub 2016 Apr 27.

8.

Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.

Aykul S, Martinez-Hackert E.

J Biol Chem. 2016 May 13;291(20):10792-804. doi: 10.1074/jbc.M115.713487. Epub 2016 Mar 9.

9.

Activin B Induces Noncanonical SMAD1/5/8 Signaling via BMP Type I Receptors in Hepatocytes: Evidence for a Role in Hepcidin Induction by Inflammation in Male Mice.

Canali S, Core AB, Zumbrennen-Bullough KB, Merkulova M, Wang CY, Schneyer AL, Pietrangelo A, Babitt JL.

Endocrinology. 2016 Mar;157(3):1146-62. doi: 10.1210/en.2015-1747. Epub 2016 Jan 6.

10.

The protein kinase LKB1 negatively regulates bone morphogenetic protein receptor signaling.

Raja E, Tzavlaki K, Vuilleumier R, Edlund K, Kahata K, Zieba A, Morén A, Watanabe Y, Voytyuk I, Botling J, Söderberg O, Micke P, Pyrowolakis G, Heldin CH, Moustakas A.

Oncotarget. 2016 Jan 12;7(2):1120-43. doi: 10.18632/oncotarget.6683.

11.

MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC.

Wang X, Chen X, Meng Q, Jing H, Lu H, Yang Y, Cai L, Zhao Y.

Sci Rep. 2015 Dec 1;5:17618. doi: 10.1038/srep17618.

12.

p53 and ΔNp63α Coregulate the Transcriptional and Cellular Response to TGFβ and BMP Signals.

Balboni AL, Cherukuri P, Ung M, DeCastro AJ, Cheng C, DiRenzo J.

Mol Cancer Res. 2015 Apr;13(4):732-42. doi: 10.1158/1541-7786.MCR-14-0152-T. Epub 2015 Feb 19.

13.

The role of Smad7 in oral mucositis.

Bian L, Han G, Zhao CW, Garl PJ, Wang XJ.

Protein Cell. 2015 Mar;6(3):160-9. doi: 10.1007/s13238-014-0130-4. Epub 2015 Jan 8. Review.

14.

Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation.

Horbelt D, Boergermann JH, Chaikuad A, Alfano I, Williams E, Lukonin I, Timmel T, Bullock AN, Knaus P.

J Biol Chem. 2015 Feb 6;290(6):3390-404. doi: 10.1074/jbc.M114.604397. Epub 2014 Nov 3.

15.

Brightfield proximity ligation assay reveals both canonical and mixed transforming growth factor-β/bone morphogenetic protein Smad signaling complexes in tissue sections.

Flanders KC, Heger CD, Conway C, Tang B, Sato M, Dengler SL, Goldsmith PK, Hewitt SM, Wakefield LM.

J Histochem Cytochem. 2014 Dec;62(12):846-63. doi: 10.1369/0022155414550163. Epub 2014 Aug 20.

16.

Two faces of TGF-beta1 in breast cancer.

Zarzynska JM.

Mediators Inflamm. 2014;2014:141747. doi: 10.1155/2014/141747. Epub 2014 May 7. Review.

17.

Bone morphogenetic proteins and their antagonists: current and emerging clinical uses.

Ali IH, Brazil DP.

Br J Pharmacol. 2014 Aug;171(15):3620-32. doi: 10.1111/bph.12724. Review.

18.

Role of TGF-β in breast cancer bone metastases.

Chiechi A, Waning DL, Stayrook KR, Buijs JT, Guise TA, Mohammad KS.

Adv Biosci Biotechnol. 2013 Oct 1;4(10C):15-30.

19.

Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development.

Holtzhausen A, Golzio C, How T, Lee YH, Schiemann WP, Katsanis N, Blobe GC.

FASEB J. 2014 Mar;28(3):1248-67. doi: 10.1096/fj.13-239178. Epub 2013 Dec 5.

20.

Growth differentiation factor 5 is a key physiological regulator of dendrite growth during development.

Osório C, Chacón PJ, Kisiswa L, White M, Wyatt S, Rodríguez-Tébar A, Davies AM.

Development. 2013 Dec;140(23):4751-62. doi: 10.1242/dev.101378. Epub 2013 Oct 30.

Supplemental Content

Support Center